2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-15608R
    MPTP hydrochloride (Standard) 23007-85-4
    Iproniazid (phosphate) (Standard) is the analytical standard of Iproniazid (phosphate). This product is intended for research and analytical applications. Iproniazid phosphate is a non-selective, irreversible monoamine oxidase (MAO) inhibitor of the hydrazine class. Iproniazid phosphate has antidepressive activity.
    MPTP hydrochloride (Standard)
  • HY-156102
    c-ABL-IN-5 98%
    c-ABL-IN-5 is a selective c-Abl inhibitor with neuroprotective effects. c-ABL-IN-5 has blood-brain barrier penetrability, metabolic stability and good pharmacokinetic properties. When c-ABL-IN-5 is labeled with [18F] (compound [18F]3), it can be used as a tracer to evaluate disease-modifying efficacy by complementary positron emission tomography (PET). c-ABL-IN-5 can be used in the study of neurodegenerative diseases such as Parkinson's disease (PD).
    c-ABL-IN-5
  • HY-156104
    CaMKIIα-PHOTAC 2481744-33-4 98%
    CaMKIIα-PHOTAC is a photochemically targeted chimera (PHOTAC) targeting Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα). Molecules such as PHOTAC can catalyze the ubiquitination and degradation of target proteins through the endogenous proteasome under specific wavelengths of light. CaMKIIα-PHOTAC reduces synaptic function under light conditions, and it attenuates the intensity of evoked field excitatory postsynaptic potentials in the mouse hippocampus in response to physiological stimuli. CaMKIIα-PHOTAC plays a critical role in maintaining long-term potentiation and memory capacity in subcellular dendritic domains.
    CaMKIIα-PHOTAC
  • HY-156128
    Imidafenacin Metabolite M4 503598-17-2 98%
    Imidafenacin Metabolite M4 is a metabolite of the muscarinic acetylcholine receptor antagonist Imidafenacin (HY-B0662).
    Imidafenacin Metabolite M4
  • HY-156167
    LRRK2-IN-10 2704562-80-9 98%
    LRRK2-IN-10 (compound 34) is a potent, mutation-selective, and brain penetrant G2019S-LRRK2 kinase inhibitor with IC50s of 11 nM and 5.2 nM for G2019S-LRRK2 pS935 and G2019S-LRRK2 pS1292, respectively. LRRK2-IN-10 has the potential for Parkinson's disease research.
    LRRK2-IN-10
  • HY-156179
    DDC 2′,3′-O-disulfate 98%
    DDC 2′,3′-O-disulfate (compound 4) prevents the fibrillization and oligomerization of Aβ42. DDC 2′,3′-O-disulfate has the potential for Alzheimer's disease (AD) research.
    DDC 2′,3′-O-disulfate
  • HY-156180
    DDC 3′-O-β-D glucuronide 98%
    DDC 3′-O-β-D glucuronide (compound 5) is a drug metabolite that can prevent the fibrillization and oligomerization of Aβ42. DDC 3′-O-β-D glucuronide has potential for the research of Alzheimer's disease.
    DDC 3′-O-β-D glucuronide
  • HY-156348
    MAO-B-IN-26 38470-71-2 98%
    MAO-B-IN-26 (Compound IC9) is a MAO-B and acetylcholinesterase inhibitor. MAO-B-IN-26 protects SH?SY5Y cells against Aβ induced cytotoxicity, morphological changes, ROS generation and membrane damage. MAO-B-IN-26 also inhibits Aβ induced autophagy and apoptosis. MAO-B-IN-26 can be used as a neuroprotective agent against Alzheimer’s disease.
    MAO-B-IN-26
  • HY-156356
    AChE-IN-42 98%
    AChE-IN-42 (Compound 28) is an AChE inhibitor (Ki: 0.44?μM).
    AChE-IN-42
  • HY-156358
    AChE-IN-43 98%
    AChE-IN-43 is a potent and selective inhibitor of AChE with a Ki of 0.41 μM. AChE-IN-43 can be used in study neurological disease.
    AChE-IN-43
  • HY-156372
    AChE-IN-44 2758685-58-2 98%
    AChE-IN-44 (Compound Tap4) is an AChE inhibitor. AChE-IN-44 can be converted into the thiazole salt AChE inhibitor Tat2.
    AChE-IN-44
  • HY-156399
    KR-27425 98%
    AChE activator 1 (compound 13) is a non-pyridinium oxime reactivator of paraoxon-inhibited acetylcholinesterase(AChE).
    KR-27425
  • HY-156434
    PDE11A4-IN-1 3027607-92-4 98%
    PDE11A4-IN-1 (compound 23b) is a potent and selective PDE11A4 inhibitor with an IC50 of 12 nM. PDE11A4-IN-1 show high selectivity for PDE11A4 over PDE1, PDE2, PDE7, PDE8, and PDE9.
    PDE11A4-IN-1
  • HY-156534
    5-HT2A&5-HT2C agonist-1 1640-02-4 98%
    5-HT2A&5-HT2C agonist-1 (Example 2) is a 5-HT2A & 5-HT2C agonist, with IC50s of 196 nM and 0.9 nM respectively. 5-HT2A&5-HT2C agonist-1 can be used for research of depression, alcoholism, tobacco and cocaine addiction, inflammation, cluster headache, PTSD, seizure disorders and other CNS disorders.
    5-HT2A&5-HT2C agonist-1
  • HY-156614
    Icalcaprant 2227384-17-8 98%
    Icalcaprant is a kappa-opioid receptor antagonist.
    Icalcaprant
  • HY-156626
    Nevadistinel 2181816-92-0 98%
    Nevadistinel (NYX-458; NYX-3054) is a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptor. Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer's disease, Parkinson's disease, Lewy body disease.
    Nevadistinel
  • HY-156634
    Risevistinel 2591344-26-0 98%
    Risevistinel (NYX-783) is a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptor. Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer's disease, Parkinson's disease, Lewy body disease.
    Risevistinel
  • HY-156664
    Calcium Channel antagonist 3 687573-14-4 ≥98.0%
    Calcium Channel antagonist 3 (compound 397) is an inhibitor of voltage-gated calcium channels with an IC50 value of 5-20μM.
    Calcium Channel antagonist 3
  • HY-156669
    Calcium Channel antagonist 4 687574-49-8
    Calcium Channel antagonist 4 (compound 189) is an inhibitor of voltage-gated calcium channels with an IC50 value of 5-20μM.
    Calcium Channel antagonist 4
  • HY-156754
    3β-Hydroxy-lup-20(29)-en-16-one 65043-60-9 98%
    3β-Hydroxy-lup-20(29)-en-16-one (compound 9) is a dual inhibitor of AChE and BChE, with selectivity for BChE (IC50: 28.9 μM).
    3β-Hydroxy-lup-20(29)-en-16-one
Cat. No. Product Name / Synonyms Application Reactivity